|
[1] CHEN JG, ZHANG SW.Liver cancer epidemic in China:past, present and future[J].Semin Cancer Biol, 2011, 21 (1) :59-69.
|
|
[2] LLOVET JM, BURROUGHS A, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917.
|
|
[3]LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
|
[4]MORIMOTO M, NUMATA K, KONDO M, et al.Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib[J].Hepatol Res, 2011, 41 (4) :296-302.
|
|
[5]PALUCKA K, BANCHEREAU J.Cancer immunotherapy via dendritic cells[J].Nat Rev Cancer, 2012, 12 (4) :265-277.
|
|
[6] BRAY SM, VUJANOVIC L, BUTTERFIELD LH.Dendritic cellbased vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients[J].Clin Dev Immunol, 2011, 2011:249281.
|
|
[7] ELANSARY M, MOGAWER S, ELHAMID SA, et al.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J].J Cancer Res Clin Oncol, 2013, 139 (1) :39-48.
|
|
[8] CABILLIC F, TOUTIRAIS O, LAVOUV, et al.Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients[J].Cancer Immunol Immunother, 2010, 59 (11) :1611-1619.
|
|
[9] NAKAMOTO Y, MIZUKOSHI E, KITAHARA M, et al.Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J].Clin Exp Immunol, 2011, 163 (2) :165-177.
|
|
[10] GE C, XING Y, WANG Q, et al.Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432[J].Int Immunopharmacol, 2011, 11 (12) :2200-2207.
|
|
[11] YANG X, ZHU H, HU Z.Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth[J].Vaccine, 2010, 28 (43) :7130-7135.
|
|
[12] PENG W, ZHAO G, MA Y, et al.Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo[J].Vaccine, 2011, 29 (18) :3501-3506.
|
|
[13] CHEN Y, HUANG A, GAO M, et al.Potential therapeutic value of dendritic cells loaded with NYESO1 protein for the immunotherapy of advanced hepatocellular carcinoma[J].Int J Mol Med, 2013, 32 (6) :1366-1372.
|
|
[14]SU S, ZHOU H, XUE M, et al.Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models[J].Asian Pac J Cancer Prev, 2013, 14 (5) :3109-3116.
|
|
[15] TADA F, ABE M, HIROOKA M, et al.Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J].Int J Oncol, 2012, 41 (5) :1601-1609.
|
|
[16]BIRON CA.Expansion, maintenance, and memory in NK and T cells during viral infections:responding to pressures for defense and regulation[J].PLoS Pathog, 2010, 6 (3) :e1000816.
|
|
[17]CHENG M, ZHI K, GAO X, et al.Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1[J].Mol Cancer, 2013, 12 (1) :166.
|
|
[18]SPRINZL MF, REISINGER F, PUSCHNIK A, et al.Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells[J].Hepatology, 2013, 57 (6) :2358-2368.
|
|
[19]NISHIDA S, LEVI DM, TZAKIS AG.Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma[J].Curr Opin Organ Transplant, 2013, 18 (6) :690-694.
|
|
[20]JIANG W, ZHANG C, TIAN Z, et al.hIFN-αgene modification augments human natural killer cell line anti-human hepatocellular carcinoma function[J].Gene Ther, 2013, 20 (11) :1062-1069.
|
|
[21]KAWATA A, UNE Y, HOSOKAWA M, et al.Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients.Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone[J].Am J Clin Oncol, 1995, 18 (3) :257-262.
|
|
[22]PU LY, PANG RL, JIN YH, et al.Effects of hepatic artery chemotherapeutic embolization combined with perfusing LAK cells into hepatic artery after radical operation of liver cancer[J].Chin J Hepatol, 2000, 8 (3) :142-143. (in Chinese) 镤利宇, 庞瑞麟, 金银慧, 等.肝癌根治性切除术后肝动脉化疗栓塞联合LAK细胞肝动脉灌注的价值[J].中华肝脏病杂志, 2000, 8 (3) :142-143.
|
|
[23]TAKAYAMA T, MAKUUCHI M, SEKINE T, et al.Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies.A preliminary report[J].Cancer, 1991, 68 (11) :2391-2396.
|
|
[24] TAKAYAMA T, SEKINE T, MAKUUCHI M, et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial[J].Lancet, 2000, 356 (9232) :802-807.
|
|
[25]WANG FS, LIU MX, ZHANG B, et al.Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo[J].World J Gastroenterol, 2002, 8 (3) :464-468.
|
|
[26] PAN K, LI YQ, WANG W, et al.The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients[J].Ann Surg Oncol, 2013, 20 (13) :4305-4311.
|
|
[27]WANG XP, XU M, GAO HF, et al.Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma[J].World J Gastroenterol, 2013, 19 (19) :2956-2962.
|
|
[28]HUANG ZM, LI W, LI S, et al.Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J].J Immunother, 2013, 36 (5) :287-293.
|
|
[29] LI X, DAI D, SONG X, et al.A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol, 2014.[Epub ahead of print]
|
|
[30]LEE K, HWANG H, NAM KT.Immune response and the tumor microenvironment:how they communicate to regulate gastric cancer[J].Gut Liver, 2014, 8 (2) :131-139.
|
|
[31]ALTOMONTE J, EBERT O.Sorting out pandora's box:discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma[J].Front Oncol, 2014, 4:85.
|
|
[32]WILLIMSKY G, PROTZER U, KNOLLE P, et al.Adoptive Tcell therapy to treat liver cancer:is the liver microenvironment key?[J].Oncotarget, 2013, 4 (8) :1117-1118.引证本文:ZHANG Y, ZHANG MJ, JIA ZS.Research advances in cellular immunotherapy for primary hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (9) :860-864. (in Chinese) 张野, 张明杰, 贾战生.肝细胞癌细胞免疫治疗的研究进展[J].临床肝胆病杂志, 2014, 30 (9) :860-864.
|
DownLoad: